Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases

Fabrice Lucien, Vivian Lac, Daniel D Billadeau, Ayelet Borgida, Steven Gallinger, Hon S. Leong

Research output: Contribution to journalArticle

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease that is clinically asymptomatic in its early stages of development. Non-invasive testing for pancreatic cancer biomarkers would significantly improve early detection and patient care. Extracellular vesicles (EVs) are circulating tumor fragments present in the blood and may express cancer specific biomarkers that would enable early detection of pancreatic cancer. We tested the utility of a blood test enumerating EVs positive for the pancreas-specific marker Glycoprotein 2 (GP2) and the putative pancreatic cancer marker Glypican-1 (GPC1) in patients with PDAC. Various levels of GPC1-positive and GP2/GPC1-positive EVs were detected in PDAC patients but were not significantly higher than benign pancreatic disease (BPD) patients. The sensitivity and specificity of the GPC1 EV test was 26.67% and 87.50% respectively, whereas the sensitivity and specificity for the GPC1+GP2 EV test was 23.33% and 90.00% respectively. Immunohistochemistry of GPC1 expression in a tissue microarray of PDAC and various controls also did not demonstrate specificity of GPC1 to PDAC. Hence, enumeration of GPC1-positive EVs, solely or in conjunction with GP2, was unable to effectively distinguish between BPD and pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)1045-1055
Number of pages11
JournalOncotarget
Volume10
Issue number10
StatePublished - Feb 1 2019

Fingerprint

Glypicans
Pancreatic Diseases
Pancreatic Neoplasms
Glycoproteins
Adenocarcinoma
Tumor Biomarkers
Sensitivity and Specificity
Extracellular Vesicles
Hematologic Tests
Early Detection of Cancer
Pancreas
Patient Care
Immunohistochemistry

Keywords

  • Extracellular vesicles
  • Flow cytometry
  • Glypican-1
  • Liquid biopsy
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases. / Lucien, Fabrice; Lac, Vivian; Billadeau, Daniel D; Borgida, Ayelet; Gallinger, Steven; Leong, Hon S.

In: Oncotarget, Vol. 10, No. 10, 01.02.2019, p. 1045-1055.

Research output: Contribution to journalArticle

Lucien, Fabrice ; Lac, Vivian ; Billadeau, Daniel D ; Borgida, Ayelet ; Gallinger, Steven ; Leong, Hon S. / Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases. In: Oncotarget. 2019 ; Vol. 10, No. 10. pp. 1045-1055.
@article{a279195299f448a58f1c01de83eec8aa,
title = "Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease that is clinically asymptomatic in its early stages of development. Non-invasive testing for pancreatic cancer biomarkers would significantly improve early detection and patient care. Extracellular vesicles (EVs) are circulating tumor fragments present in the blood and may express cancer specific biomarkers that would enable early detection of pancreatic cancer. We tested the utility of a blood test enumerating EVs positive for the pancreas-specific marker Glycoprotein 2 (GP2) and the putative pancreatic cancer marker Glypican-1 (GPC1) in patients with PDAC. Various levels of GPC1-positive and GP2/GPC1-positive EVs were detected in PDAC patients but were not significantly higher than benign pancreatic disease (BPD) patients. The sensitivity and specificity of the GPC1 EV test was 26.67{\%} and 87.50{\%} respectively, whereas the sensitivity and specificity for the GPC1+GP2 EV test was 23.33{\%} and 90.00{\%} respectively. Immunohistochemistry of GPC1 expression in a tissue microarray of PDAC and various controls also did not demonstrate specificity of GPC1 to PDAC. Hence, enumeration of GPC1-positive EVs, solely or in conjunction with GP2, was unable to effectively distinguish between BPD and pancreatic cancer.",
keywords = "Extracellular vesicles, Flow cytometry, Glypican-1, Liquid biopsy, Pancreatic cancer",
author = "Fabrice Lucien and Vivian Lac and Billadeau, {Daniel D} and Ayelet Borgida and Steven Gallinger and Leong, {Hon S.}",
year = "2019",
month = "2",
day = "1",
language = "English (US)",
volume = "10",
pages = "1045--1055",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "10",

}

TY - JOUR

T1 - Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases

AU - Lucien, Fabrice

AU - Lac, Vivian

AU - Billadeau, Daniel D

AU - Borgida, Ayelet

AU - Gallinger, Steven

AU - Leong, Hon S.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease that is clinically asymptomatic in its early stages of development. Non-invasive testing for pancreatic cancer biomarkers would significantly improve early detection and patient care. Extracellular vesicles (EVs) are circulating tumor fragments present in the blood and may express cancer specific biomarkers that would enable early detection of pancreatic cancer. We tested the utility of a blood test enumerating EVs positive for the pancreas-specific marker Glycoprotein 2 (GP2) and the putative pancreatic cancer marker Glypican-1 (GPC1) in patients with PDAC. Various levels of GPC1-positive and GP2/GPC1-positive EVs were detected in PDAC patients but were not significantly higher than benign pancreatic disease (BPD) patients. The sensitivity and specificity of the GPC1 EV test was 26.67% and 87.50% respectively, whereas the sensitivity and specificity for the GPC1+GP2 EV test was 23.33% and 90.00% respectively. Immunohistochemistry of GPC1 expression in a tissue microarray of PDAC and various controls also did not demonstrate specificity of GPC1 to PDAC. Hence, enumeration of GPC1-positive EVs, solely or in conjunction with GP2, was unable to effectively distinguish between BPD and pancreatic cancer.

AB - Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease that is clinically asymptomatic in its early stages of development. Non-invasive testing for pancreatic cancer biomarkers would significantly improve early detection and patient care. Extracellular vesicles (EVs) are circulating tumor fragments present in the blood and may express cancer specific biomarkers that would enable early detection of pancreatic cancer. We tested the utility of a blood test enumerating EVs positive for the pancreas-specific marker Glycoprotein 2 (GP2) and the putative pancreatic cancer marker Glypican-1 (GPC1) in patients with PDAC. Various levels of GPC1-positive and GP2/GPC1-positive EVs were detected in PDAC patients but were not significantly higher than benign pancreatic disease (BPD) patients. The sensitivity and specificity of the GPC1 EV test was 26.67% and 87.50% respectively, whereas the sensitivity and specificity for the GPC1+GP2 EV test was 23.33% and 90.00% respectively. Immunohistochemistry of GPC1 expression in a tissue microarray of PDAC and various controls also did not demonstrate specificity of GPC1 to PDAC. Hence, enumeration of GPC1-positive EVs, solely or in conjunction with GP2, was unable to effectively distinguish between BPD and pancreatic cancer.

KW - Extracellular vesicles

KW - Flow cytometry

KW - Glypican-1

KW - Liquid biopsy

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85061029846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061029846&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 1045

EP - 1055

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 10

ER -